JBI-589

JBI-589 is a potent, selective, and orally active small molecule inhibitor of peptidylarginine deiminase 4 (PAD4), originally developed by Jubilant Therapeutics. As a non-covalent, isoform-selective inhibitor, JBI-589 blocks the citrullination of proteins, a process that plays a critical role in the formation of neutrophil extracellular traps (NETs) and the modulation of the tumor microenvironment. Preclinical studies indicate that JBI-589 reduces CXCR2 expression and inhibits neutrophil chemotaxis, leading to decreased primary tumor growth and metastasis. It has also demonstrated the ability to enhance the efficacy of immune checkpoint inhibitors in oncology models and has shown strong anti-inflammatory activity in mouse models of rheumatoid arthritis.